Survey of Satisfaction on Traditional Chinese Medicine Jing-Guan-Fang (JGF) for COVID-19 Prevention

May 12, 2020 updated by: Taipei City Hospital

Department of Chinese Medicine, Branch of Linsen, Chinese Medicine, and Kunming, Taipei City Hospital, Taipei, Taiwan Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan.

the retrospective observation study, the first line to care CAVID-19

Study Overview

Status

Unknown

Conditions

Detailed Description

The satisfaction of using nature herbal medicine for frontline medical staffs to prevent COVID-19: a retrospective clinical study.

The medical frontline staffs have the high risk to be infected during working. The stress and load were acuminated, especially when they got the similar symptoms as COVID-19. NHM has been used to early prevention for thousands of years9-12. It was well accept to take NHM for early prevention in many Asia-Pacific countries. Although many NHM remedies of COVID-19 treatment or prevention were reported, but the related study were lacking. To understand the pressure and the satisfaction of frontline medical staffs after taking JGF for early prevention we conducted this retrospective clinical study to explore the relationship in different groups.

Study Type

Observational

Enrollment (Anticipated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
      • Taipei, Taiwan, 886
        • Recruiting
        • Branch of Chinese Medicine, Taipei City Hospital
        • Contact:
        • Contact:
      • Taipei, Taiwan, 886
        • Recruiting
        • Branch of Linsen Chinese Medicine and Kunming, Taipei City Hospital
        • Contact:
        • Contact:
      • Taipei, Taiwan, 886
        • Recruiting
        • Taipei City Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The first-line medical staff who take care of COVID-19 patients in public hospital northern Taiwan., and the self-quarantine who have contacted with history.

Some of the population will take natural herbal medicine to prevent COVID-19 infection.

Description

Inclusion Criteria:

  • The person first-line medical staff in hospital
  • the inspection personnel in airport
  • self-quarantine at home.
  • self-quarantine at office.

Exclusion Criteria:

  • no willing to participate
  • allergy to herbal medicine
  • severe illness evaluated by physician

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the number confirmed COVID-19 cases
Time Frame: 8 weeks
The isolated person and first-line care person who taking JGF
8 weeks
The person with COVID-19 like symptoms
Time Frame: 8 weeks
The isolated person and first-line care person who taking JGF
8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The improving rate of COVID-19 like symptoms
Time Frame: 8 weeks
The isolated person and first-line care person who taking JGF
8 weeks
The satisfaction% to taking JGF
Time Frame: 8 weeks
The isolated person and first-line care person who taking JGF
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Taipei City Hospital

Collaborators

National Yang Ming University

Investigators

  • Study Director: Chung-HUa Hsu, PhD, Taipei City Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 20, 2020

Primary Completion (Anticipated)

May 20, 2020

Study Completion (Anticipated)

May 30, 2020

Study Registration Dates

First Submitted

May 12, 2020

First Submitted That Met QC Criteria

May 12, 2020

First Posted (Actual)

May 14, 2020

Study Record Updates

Last Update Posted (Actual)

May 14, 2020

Last Update Submitted That Met QC Criteria

May 12, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TCHIRB-10904015-E

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Corona Virus Infection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe